


Udifitimod

Cat. No.:	HY-119245
CAS No.:	1883345-06-9
Molecular Formula:	C ₂₅ H ₃₃ NO ₂
Molecular Weight:	379.54
Target:	LPL Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Udifitimod (BMS-986166) is a potent, selective and orally active S1P1R modulator. Udifitimod has the potential for the research of autoimmune diseases ^{[1][2]} .																
IC₅₀ & Target	S1P1R																
In Vivo	<p>Udifitimod (0.1, 0.5 mg/kg; p.o.; once daily for 21 days) shows anti-inflammation activity in autoimmune encephalomyelitis model ^[1].</p> <p>Udifitimod (0.1, 0.5 mg/kg; p.o.; once daily for 50 days) reduces the clinical score as well as the paw histology score in the collagen-induced arthritis (CIA) model^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>6-8 weeks, C57BL/6 female mice (autoimmune encephalomyelitis model (EAE))^[2]</td> </tr> <tr> <td>Dosage:</td> <td>0.1, 0.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.; once daily for 21 days</td> </tr> <tr> <td>Result:</td> <td>Showed a dose-dependent reduction in clinical scores for inflammation.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>DBA/1 mice (collagen-induced arthritis (CIA) model)^[2]</td> </tr> <tr> <td>Dosage:</td> <td>0.1, 0.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.; once daily for 50 days</td> </tr> <tr> <td>Result:</td> <td>Dose dependently reduced both the clinical score as well as the paw histology score following the dosing regimens.</td> </tr> </table>	Animal Model:	6-8 weeks, C57BL/6 female mice (autoimmune encephalomyelitis model (EAE)) ^[2]	Dosage:	0.1, 0.5 mg/kg	Administration:	P.o.; once daily for 21 days	Result:	Showed a dose-dependent reduction in clinical scores for inflammation.	Animal Model:	DBA/1 mice (collagen-induced arthritis (CIA) model) ^[2]	Dosage:	0.1, 0.5 mg/kg	Administration:	P.o.; once daily for 50 days	Result:	Dose dependently reduced both the clinical score as well as the paw histology score following the dosing regimens.
Animal Model:	6-8 weeks, C57BL/6 female mice (autoimmune encephalomyelitis model (EAE)) ^[2]																
Dosage:	0.1, 0.5 mg/kg																
Administration:	P.o.; once daily for 21 days																
Result:	Showed a dose-dependent reduction in clinical scores for inflammation.																
Animal Model:	DBA/1 mice (collagen-induced arthritis (CIA) model) ^[2]																
Dosage:	0.1, 0.5 mg/kg																
Administration:	P.o.; once daily for 50 days																
Result:	Dose dependently reduced both the clinical score as well as the paw histology score following the dosing regimens.																

REFERENCES

[1]. Bihorel S, et al. Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan;10(1):8-21.

[2]. Gilmore JL, et al. Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials. J Med Chem. 2019 Mar 14;62(5):2265-2285.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA